Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of MK-0594 in overactive bladder
2005-005606-23Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of serlopitant in overactive bladder (OAB) (8 arms), sponsored by Merck & Co. Started Jan 2006; status: terminated.
02
Drugs
serlopitant
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-005606-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005606-23.